| | Type | L # | Hits | Search Text | DBs | Time Stamp | Comments | Error Definition | Errors |
|---|---|---|---|---|---|---|---|---|---|
| 1 | BRS | L1 | 23 | His-phe-Arg-Trp | USPAT; US-PGPUB; EPO; JPO; DERWENT | 2003/09/13 12:37 | | | 0 |
| 2 | BRS | L2 | 10 | His-D-phe-Arg-Trp | USPAT; US-PGPUB; EPO; JPO; DERWENT | 2003/09/13 12:37 | | | 0 |
| 3 | BRS | L3 | 3252 | cyclic adj peptide | USPAT; US-PGPUB; EPO; JPO; DERWENT | 2003/09/13 12:37 | | | 0 |
| 4 | BRS | L4 | 2 | (1 or 2) same 3 | USPAT; US-PGPUB; EPO; JPO; DERWENT | 2003/09/13 12:39 | | | 0 |
| 5 | BRS | L5 | 4 | composition same (1 or 2) | USPAT; US-PGPUB; EPO; JPO; DERWENT | 2003/09/13 12:42 | | | 0 |
| 6 | BRS | L6 | 269 | sexual adj response | USPAT; US-PGPUB; EPO; JPO; DERWENT | 2003/09/13 12:42 | | | 0 |
| 7 | BRS | L7 | 3 | (1 or 2) same 6 | USPAT; US-PGPUB; EPO; JPO; DERWENT | 2003/09/13 12:43 | | | 0 |
| 8 | BRS | L8 | 327 | melanocortin adj receptor | USPAT; US-PGPUB; EPO; JPO; DERWENT | 2003/09/13 12:45 | | | 0 |
| 9 | BRS | L9 | 3 | melanocortin adj receptor adj specific adj peptide | USPAT; US-PGPUB; EPO; JPO; DERWENT | 2003/09/13 12:46 | | | 0 |
| 10 | BRS | L10 | 389 | alpha-MSH | USPAT; US-PGPUB; EPO; JPO; DERWENT | 2003/09/13 12:47 | | | 0 |
| 11 | BRS | L11 | 137 | 10 same (fragment or analog) | USPAT; US-PGPUB; EPO; JPO; DERWENT | 2003/09/13 12:47 | | | 0 |
| 12 | BRS | L12 | 3018 | sexual adj dysfunction | USPAT; US-PGPUB; EPO; JPO; DERWENT | 2003/09/13 12:48 | | | 0 |
| 13 | BRS | L13 | 10 | (6 or 12) same (1 or 2 or 11) | USPAT; US-PGPUB; EPO; JPO; DERWENT | 2003/09/13 12:50 | | | 0 |
| 14 | BRS | L14 | 3 | blood adj christine.in. | USPAT; US-PGPUB; EPO; JPO; DERWENT | 2003/09/13 12:51 | | | 0 |
| 15 | BRS | L15 | 4 | shadiack adj annette.in. | USPAT; US-PGPUB; EPO; JPO; DERWENT | 2003/09/13 12:51 | | | 0 |
| 16 | BRS | L16 | 2 | bernstein adj joanna.in. | USPAT; US-PGPUB; EPO; JPO; DERWENT | 2003/09/13 12:52 | | | 0 |

| | Type | L # | Hits | Search Text | DBs | Time Stamp | Comments | Error Definition | Errors |
|---|---|---|---|---|---|---|---|---|---|
| 17 | BRS | L17 | 2 | herbert adj guy.in. | USPAT; US-PGPUB; EPO; JPO; DERWENT | 2003/09/13 12:52 | | | 0 |
| 18 | BRS | L18 | 5 | ( 14 or 15 or 16 or 17) | USPAT; US-PGPUB; EPO; JPO; DERWENT | 2003/09/13 12:53 | | | 0 |
| 19 | BRS | L19 | 2 | ( 14 or 15 or 16 or 17) and (1 or 2) | USPAT; US-PGPUB; EPO; JPO; DERWENT | 2003/09/13 12:53 | | | 0 |
| 20 | BRS | L20 | 24 | 1 or 2 | USPAT; US-PGPUB; EPO; JPO; DERWENT | 2003/09/13 13:06 | | | 0 |
| 21 | BRS | L21 | 2 | 6051555.pn. | USPAT; US-PGPUB; EPO; JPO; DERWENT | 2003/09/13 13:07 | | | 0 |

```
$
FILE 'MEDLINE' ENTERED AT 13:30:55 ON 13 SEP 2003

FILE 'CAPLUS' ENTERED AT 13:30:55 ON 13 SEP 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'BIOSIS' ENTERED AT 13:30:55 ON 13 SEP 2003
COPYRIGHT (C) 2003 BIOLOGICAL ABSTRACTS INC.(R)

FILE 'EMBASE' ENTERED AT 13:30:55 ON 13 SEP 2003
COPYRIGHT (C) 2003 Elsevier Science B.V.  All rights reserved.

FILE 'SCISEARCH' ENTERED AT 13:30:55 ON 13 SEP 2003
COPYRIGHT 2003 THOMSON ISI

FILE 'AGRICOLA' ENTERED AT 13:30:55 ON 13 SEP 2003

=> s His-Phe-arg-Trp-oh
L1            1 HIS-PHE-ARG-TRP-OH

=> d l1 1 ibib abs

L1   ANSWER 1 OF 1  CAPLUS  COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER:         1977:439803  CAPLUS
DOCUMENT NUMBER:          87:39803
TITLE:                    Des-N.alpha.1-acetyl-.alpha.-melanotropin.  A
                          synthetic substrate for specific N-terminal directed
                          enzymic acetylation
AUTHOR(S):                Smeets, Paul; Granger, Michele; Van Nispen, Johannes
                          W.; Bloemendal, Hans; Tesser, Godefridus I.
CORPORATE SOURCE:         Dep. Org. Chem., Cathol. Univ. Nijmegen, Nijmegen,
                          Neth.
SOURCE:                   International Journal of Peptide & Protein Research
                          (1977), 9(1), 52-6
                          CODEN: IJPPC3; ISSN: 0367-8377
DOCUMENT TYPE:            Journal
LANGUAGE:                 English
AB   R-Ser-Tyr-Ser-Met-Glu-His-Phe-Arg-Trp-Gly-Lys-Pro-Val-NH2 (I, R = H),
     deacetyl-MSH, was prepd. by coupling BOC-Ser-Tyr-Ser-Met-Glu(OCMe3)-
       ***His***  -  ***Phe***  -  ***Arg***  -  ***Trp***  -  ***OH***   (BOC =
     Me3CO2C) to H-Lys(Msc)-Pro-Val-NH2 (II, Msc = MeSO2CH2CH2O2C) with
     dicyclohexylcarbodiimide and deblocking the resulting protected
     tridecapeptide amide with CF3CO2H for BOC and CMe3 groups and NaOH for the
     Msc group.  BOC-Lys(Msc)-OC6H4NO2-4 was prepd. and coupled to
     H-Pro-Val-NH2 to give BOC-Lys(Msc)-Pro-Val-NH2, which was BOC-deblocked
     with HCl to give II.  I (R = H) was selectively acetylated at the
     N-terminal NH2 by an enzyme system in a cell-free ext. of calf eye lenses
     to give I (R = Ac) (.alpha.-MSH).  The latter was prepd., but was not
     acetylated at the side chain NH2 by the above enzyme system.
     R1-Ser-Tyr-Ser-Met-Glu(OR2)-His-Phe-Arg-Trp-Gly-Lys(R3)-Pro-Val-NH2 (R1 =
     R2 = H, R3 = Msc, Ac; R1 = Ac, R2 = H, R3 = Msc, Ac; R1 = BOC, R2 = CMe3,
     R3 = H, Ac) were also prepd.


=> s his-D-phe-arg-trp-oh
L2            0 HIS-D-PHE-ARG-TRP-OH

=> log y
COST IN U.S. DOLLARS                                  SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                      26.25      26.46

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)            SINCE FILE      TOTAL
                                                         ENTRY    SESSION
CA SUBSCRIBER PRICE                                      -0.65      -0.65

STN INTERNATIONAL LOGOFF AT 13:32:51 ON 13 SEP 2003
```

```
FILE 'MEDLINE' ENTERED AT 13:15:17 ON 13 SEP 2003

FILE 'CAPLUS' ENTERED AT 13:15:17 ON 13 SEP 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'BIOSIS' ENTERED AT 13:15:17 ON 13 SEP 2003
COPYRIGHT (C) 2003 BIOLOGICAL ABSTRACTS INC.(R)

FILE 'EMBASE' ENTERED AT 13:15:17 ON 13 SEP 2003
COPYRIGHT (C) 2003 Elsevier Science B.V.  All rights reserved.

FILE 'SCISEARCH' ENTERED AT 13:15:17 ON 13 SEP 2003
COPYRIGHT 2003 THOMSON ISI

FILE 'AGRICOLA' ENTERED AT 13:15:17 ON 13 SEP 2003

=> s His-Phe-Arg-Trp
L1          411 HIS-PHE-ARG-TRP

=> s His-D-phe-Arg-Trp
L2           73 HIS-D-PHE-ARG-TRP

=> s l1 or l2
L3          462 L1 OR L2

=> s composition (p) l3
L4           20 COMPOSITION (P) L3

=> duplicateremove l4
ENTER REMOVE, IDENTIFY, ONLY, OR (?):remove l4
'REMOVE L28' IS NOT VALID HERE
Enter "REMOVE" to identify and remove duplicate answers.
Enter "IDENTIFY" to identify duplicate answers in the answer set.
Enter "ONLY" to identify and create an answer set containing only
duplicate records.
ENTER REMOVE, IDENTIFY, ONLY, OR (?):duplicate remove
'DUPLICATE REMOVE' IS NOT VALID HERE
Enter "REMOVE" to identify and remove duplicate answers.
Enter "IDENTIFY" to identify duplicate answers in the answer set.
Enter "ONLY" to identify and create an answer set containing only
duplicate records.
ENTER REMOVE, IDENTIFY, ONLY, OR (?):remove
DUPLICATE PREFERENCE IS 'MEDLINE, CAPLUS, BIOSIS, EMBASE, SCISEARCH'
KEEP DUPLICATES FROM MORE THAN ONE FILE?  Y/(N):n
PROCESSING COMPLETED FOR L4
L5            9 DUPLICATE REMOVE L4 (11 DUPLICATES REMOVED)

=> d l5 1-9 ibib abs

L5   ANSWER 1 OF 9  BIOSIS  COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC. on STN
ACCESSION NUMBER:   2003:323715  BIOSIS
DOCUMENT NUMBER:    PREV200300323715
TITLE:              Compositions and methods for treatment of sexual
                    dysfunction.
AUTHOR(S):          Blood, Christine H.; Shadiack, Annette M. (1); Bernstein,
                    Joanna K.; Herbert, Guy H.
CORPORATE SOURCE:   (1) Sommerset, NJ, USA USA
                    ASSIGNEE: Palatin Technologies, Inc., Cranbury, NJ, USA
PATENT INFORMATION: US 6579968 June 17, 2003
SOURCE:             Official Gazette of the United States Patent and Trademark
                    Office Patents, (June 17 2003) Vol. 1271, No. 3, pp. No
                    Pagination. http://www.uspto.gov/web/menu/patdata.html.
                    e-file.
                    ISSN: 0098-1133.
DOCUMENT TYPE:      Patent
LANGUAGE:           English
AB      ***Compositions***  and methods are provided for treatment of sexual
     dysfunction in mammals, including male sexual dysfunction, such as
     erectile dysfunction, and female sexual dysfunction. In one embodiment, a
     peptide-based  ***composition***  including the peptide sequence
     Ac-Nle-cyclo(-Asp-  ***His***  -  ***D***  -  ***Phe***  -  ***Arg***  -
       ***Trp***  -Lys)-OH is administered. Methods of administration include
     injection, oral, nasal and mucosal administration.
```

L5 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 2002:595493 CAPLUS
DOCUMENT NUMBER: 137:145614
TITLE: Pharmaceutical compositions containing a peptide for treatment of sexual dysfunction
INVENTOR(S): Blood, Christine H.; Shadiack, Annette M.; Bernstein, Joanna K.; Herbert, Guy H.
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 20 pp., Cont.-in-part of U.S. Ser. No. 606,501.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| US 2002107182 | A1 | 20020808 | US 2002-40547 | 20020104 |
| US 6579968 | B1 | 20030617 | US 2000-606501 | 20000628 |

PRIORITY APPLN. INFO.: US 1999-142346P P 19990629
US 2000-194987P P 20000405
US 2000-606501 A2 20000628

AB ***Compns*** . and methods are provided for treatment of sexual dysfunction in mammals, including male sexual dysfunction, such as erectile dysfunction, and female sexual dysfunction. In one embodiment, a peptide-based ***compn*** . including the peptide sequence Ac-Nle-cyclo(-Asp- ***His*** - ***D*** - ***Phe*** - ***Arg*** - ***Trp*** -Lys)-OH (I) is administered. Methods of administration include injection, oral, nasal and mucosal administration. I was dissolved in a 50 mM citrate, pH approx. 6.0, at a concn. of .825 mg per mL to obtain a nasal soln. Nasal administration of I at a concn. of 25 .mu.k/kg induced 100% penile erection in rats for 2 times in 30 min.

L5 ANSWER 3 OF 9 CAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 2001:12284 CAPLUS
DOCUMENT NUMBER: 134:76409
TITLE: Compositions and methods for treatment of sexual dysfunction
INVENTOR(S): Blood, Christine H.; Shadiack, Annette M.; Bernstein, Joanna K.; Herbert, Guy W.
PATENT ASSIGNEE(S): Palatin Technologies Inc., USA
SOURCE: PCT Int. Appl., 33 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| WO 2001000224 | A1 | 20010104 | WO 2000-US18217 | 20000629 |
| W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | |
| RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG | | | | |
| US 6579968 | B1 | 20030617 | US 2000-606501 | 20000628 |
| BR 2000012200 | A | 20020326 | BR 2000-12200 | 20000629 |
| EP 1196184 | A1 | 20020417 | EP 2000-950283 | 20000629 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO | | | | |
| JP 2003503357 | T2 | 20030128 | JP 2001-505933 | 20000629 |

PRIORITY APPLN. INFO.: US 1999-142346P P 19990629
US 2000-194987P P 20000405
US 2000-606501 A 20000628
WO 2000-US18217 W 20000629

AB ***Compns*** . and methods are provided for the treatment of sexual dysfunctions in mammals, such as erectile dysfunction and female sexual dysfunction. In one embodiment, a peptide-based ***compn*** . including the peptide sequence Ac-Nle-cyclo(-Asp- ***His*** - ***D*** - ***Phe*** - ***Arg*** - ***Trp*** -Lys)-OH is administered. Methods of administration include injection, oral, nasal and mucosal

administration.
REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 4 OF 9 MEDLINE on STN DUPLICATE 1
ACCESSION NUMBER: 92270473 MEDLINE
DOCUMENT NUMBER: 92270473 PubMed ID: 1667689
TITLE: Detection of a novel sequence change in the major form of alpha-MSH isolated from the intermediate pituitary of the reptile, Anolis carolinensis.
AUTHOR: Dores R M; Lancha A; Rand-Weaver M; Jankelow L; Adamczyk D L
CORPORATE SOURCE: University of Denver, Department of Biological Sciences, CO 80208.
CONTRACT NUMBER: RR06565 (NCRR)
SOURCE: PEPTIDES, (1991 Nov-Dec) 12 (6) 1261-6.
Journal code: 8008690. ISSN: 0196-9781.
PUB. COUNTRY: United States
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 199206
ENTRY DATE: Entered STN: 19920710
Last Updated on STN: 19920710
Entered Medline: 19920622
AB Intermediate pituitaries of the reptile, Anolis carolinensis, were separately pulse labeled with [3H]Trp and [3H]Tyr. The major form of alpha-MSH was purified by immunoprecipitation and isolated by reverse phase HPLC. Tryptic peptide analysis indicated that the [3H]Trp-labeled C-terminal fragment of Anolis alpha-MSH had the same retention time as mammalian ACTH(9-13) amide; however, the [3H]Tyr-labeled N-terminal fragment did not coelute with either mammalian ACTH(1-8) or N-acetyl-ACTH(1-8). Purification of alpha-MSH from 76 Anolis intermediate pituitaries confirmed that a sequence change had occurred in the N-terminal region of Anolis alpha-MSH. The tissues were acid extracted and purified by Sephadex G-25 chromatography and reverse phase HPLC to yield 4.5 micrograms of purified Anolis alpha-MSH for amino acid ***composition*** analysis and automated Edman degradation sequence analysis. The major form of Anolis alpha-MSH is nonacetylated and has the following novel primary sequence: Ser-Tyr-Ala-Met-Glu- ***His*** - ***Phe*** - ***Arg*** - ***Trp*** -Gly-Lys-Pro(Val-amide). The presence of Val-amide was verified by immunological analysis, tryptic peptide analysis and amino acid ***composition*** analysis.

L5 ANSWER 5 OF 9 MEDLINE on STN DUPLICATE 2
ACCESSION NUMBER: 91348465 MEDLINE
DOCUMENT NUMBER: 91348465 PubMed ID: 1652532
TITLE: Characterization of chicken ACTH and alpha-MSH: the primary sequence of chicken ACTH is more similar to Xenopus ACTH than to other avian ACTH.
AUTHOR: Hayashi H; Imai K; Imai K
CORPORATE SOURCE: Department of Protein Chemistry, Faculty of General Studies, Gunma University, Maebashi, Japan.
SOURCE: GENERAL AND COMPARATIVE ENDOCRINOLOGY, (1991 Jun) 82 (3) 434-43.
Journal code: 0370735. ISSN: 0016-6480.
PUB. COUNTRY: United States
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 199110
ENTRY DATE: Entered STN: 19911020
Last Updated on STN: 19911020
Entered Medline: 19911003
AB Adrenocorticotropic (ACTH) and melanocyte stimulating (MSH) hormones have been demonstrated in the same cells in the cephalic half of the pars distalis of the chicken pituitary glands in three ways: (I) immunohistochemistry, (II) radioimmunoassay (RIA) using both anti-human or porcine ACTH and synthetic alpha-MSH antibodies, and (III) isolation and purification, followed by the determination of amino acid ***compositions*** of both hormones. The contents of ACTH and alpha-MSH are estimated by RIA to be 1600 and 10 ng/gland, respectively. ACTH missed 1 (des-Phe39-ACTH) or 2 residues (des-Glu38, Phe39-ACTH) from the C-terminal portion was also isolated. The recoveries of these ACTHs are differed from preparation to preparation. The complete amino acid sequence of chicken ACTH (39 residues) has been determined as NH2-Ser-Tyr-Ser-Met-Glu- ***His*** - ***Phe*** - ***Arg*** -

***Trp*** -Gly-Lys-Pro-Val-Gly-Arg-Lys-Arg- Arg- Pro-Ile-Lys-Val-Tyr-Pro-Asn-Gly-Val-Asp-Glu-Glu-Ser-Ala-Glu-Ser-Tyr-Pro- Met-Glu-Phe-OH Strikingly the amino acid sequence of chicken ACTH shows a closer resemblance to that from an amphibian, Xenopus (3 residue substitution) than that from another bird, the ostrich (7 residue substitution) or the turkey (at least 9 residue substitution).

L5 ANSWER 6 OF 9 MEDLINE on STN DUPLICATE 3
ACCESSION NUMBER: 90013917 MEDLINE
DOCUMENT NUMBER: 90013917 PubMed ID: 2552247
TITLE: Melanin concentrating hormone. V. Isolation and characterization of alpha-melanocyte-stimulating hormone from frog pituitary glands.
AUTHOR: Tonon M C; Desrues L; Lazure C; Jenks B G; Chretien M; Vaudry H
CORPORATE SOURCE: URA CNRS 650, Unite Affiliee a l'INSERM, Universite de Rouen, Mont-Saint-Aignan, France.
SOURCE: LIFE SCIENCES, (1989) 45 (13) 1155-61.
Journal code: 0375521. ISSN: 0024-3205.
PUB. COUNTRY: ENGLAND: United Kingdom
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 198911
ENTRY DATE: Entered STN: 19900328
Last Updated on STN: 19900328
Entered Medline: 19891109
AB The structure of alpha-melanocyte-stimulating hormone (alpha-MSH) has been determined in the pars intermedia of the frog Rana ridibunda. Pulse-chase labeling of frog neurointermediate lobes with selective amino acids revealed that the ***composition*** of frog alpha-MSH is similar to that of alpha-MSH from all mammalian species yet studied. Tryptic mapping of nexly synthetized alpha-MSH generated two fragments with the following amino acid ***composition*** : (T1) Trp, Pro, Lys, Gly, Val and (T2) Tyr, Arg, Phe, His, Ser, Glu. Concurrently, alpha-MSH was purified from 100 neurointermediate lobes to apparent homogeneity by reverse-phase HPLC. The sequence of the peptide determined by automated Edman degradation was Ser-Tyr-Ser-Met-Glu- ***His*** - ***Phe*** - ***Arg*** - ***Trp*** -Gly-Lys-Pro-Val. The structure of frog alpha-MSH is thus identical to mammalian des-N alpha-acetyl alpha-MSH and differs from the sequence of toad (Xenopus laevis) alpha-MSH only by the first residue (Ser instead of Ala). These results confirm that the sequence of alpha-MSH has been highly preserved during evolution.

L5 ANSWER 7 OF 9 CAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 1989:19047 CAPLUS
DOCUMENT NUMBER: 110:19047
TITLE: Use of melanotropin or its peptide fragments for the treatment of asthmatic and allergic diseases
INVENTOR(S): Aderhold, Dieter
PATENT ASSIGNEE(S): Fed. Rep. Ger.
SOURCE: Ger. Offen., 3 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| DE 3623019 | A1 | 19880121 | DE 1986-3623019 | 19860709 |

PRIORITY APPLN. INFO.: DE 1986-3623019 19860709
AB .alpha.-MSH, .beta.-MSH, .gamma.-MSH, and/or their peptide fragments are useful for the treatment of allergic or asthmatic diseases. A dermally applied ***compn*** . contained 2 mg melanotropin tetrapeptide ( ***His*** - ***Phe*** - ***Arg*** - ***Trp*** ) colloidally adsorbed to 12 mg Al(OH)3, a swell as 13 mL water and 7 mL EtOH. This ***compn*** . was applied to the nostrils and the areas over the sinuses and >90% of the patients showed a decrease in the symptoms related to hay fever and dust allergies.

L5 ANSWER 8 OF 9 MEDLINE on STN DUPLICATE 4
ACCESSION NUMBER: 81133559 MEDLINE
DOCUMENT NUMBER: 81133559 PubMed ID: 7470089
TITLE: Purification and characterization of a gamma-melanotropin precursor from frozen human pituitary glands.
AUTHOR: Estivariz F E; Hope J; McLean C; Lowry P J

SOURCE: BIOCHEMICAL JOURNAL, (1980 Oct 1) 191 (1) 125-32.
Journal code: 2984726R. ISSN: 0264-6021.
PUB. COUNTRY: ENGLAND: United Kingdom
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 198104
ENTRY DATE: Entered STN: 19900316
Last Updated on STN: 19900316
Entered Medline: 19810413

AB A new melanocyte-stimulating peptide has been isolated from acid extracts of frozen human pituitary glands by salt/ethanol fractionation, Sephadex G-75 gel filtration and DEAE- and cM-cellulose ion-exchange chromatography. The peptide is glycosylated, has an N-terminal tryptophan residue and an apparent mol.wt. of 16000 as estimated by sodium dodecyl sulphate/polyacrylamide-gel electrophoresis. Its amino acid analysis closely resembles residues Trp-105 to Gln-29 predicted for the common precursor protein of bovine corticotropin and beta-lipotropin by Nakanishi, Inoue, Kita, Nakamura, Chang, Cohen & Numa [(1979) Nature (London) 278, 423-427]. This fragment is expected to have melanotropin activity due to the tetrapeptide - ***His*** - ***Phe*** - ***Arg*** - ***Trp*** - (residues -51 to -48) of the predicted sequence of the common precursor. It was found to have a molar potency of 1 X 10(-5) relative to alpha-melanotropin in the frog skin bioassay. These characteristics are consistent with the isolated melanotropin peptide being a non-corticotropin, non-lipotropin peptide of the human common precursor protein of corticotropin and lipotropin. The peptide neither potentiates the adrenal weight-maintenance activity of corticotropin-(1-24)-tetracosapeptide when administered to hypophysectomized rats, nor stimulates release of non-esterified fatty acids from isolated rat epididymal cells. A second N-terminal-tryptophan glycopeptide was also isolated, which had an amino-acid ***composition*** similar to that predicted for the bovine common precursor protein, residues Trp-105 to Gly-35.

L5 ANSWER 9 OF 9 CAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 1972:46519 CAPLUS
DOCUMENT NUMBER: 76:46519
TITLE: .beta.-Ala1-Lys17,18-.beta.1-18-corticotropin-Lys18-amide
INVENTOR(S): Rittel, Werner
PATENT ASSIGNEE(S): CIBA-Geigy A.-G.
SOURCE: Ger. Offen., 25 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| DE 2124549 | A | 19711209 | DE 1971-2124549 | 19710518 |
| CH 549554 | A | 19740531 | CH 1970-7836 | 19700527 |
| US 3794632 | A | 19740226 | US 1971-145032 | 19710519 |
| NL 7107260 | A | 19711130 | NL 1971-7260 | 19710526 |
| FR 2100693 | A1 | 19720324 | FR 1971-19262 | 19710527 |
| FR 2100693 | A5 | 19720324 | | |
| HU 164014 | P | 19731228 | HU 1971-CI1119 | 19710527 |

PRIORITY APPLN. INFO.: CH 1970-7836 19700527

AB The title compd., H-.beta.-Ala-Tyr-Ser-Met-Glu- ***His*** - ***Phe*** - ***Arg*** - ***Trp*** -Gly-Lys-Pro-Val-Gly-Lys-Lys-Lys-Lys-NH2 (I), with prolonged adrenocorticotropic activity was prepd. by reaction of Boc-.beta.-Ala-Tyr-Ser-Met-Glu(OBu-tert)- ***His*** - ***Phe*** - ***Arg*** - ***Trp*** -Gly-OH.4H2O (Boc=CO2Bu-tert) with H-Lys(Boc)-Pro-Val-Gly-Lys(Boc)-Lys(Boc)-Lys(Boc)-Lys(Boc)-NH2 in the presence of N HCl, N-hydroxysuccinimide and dicyclohexylcarbodiimide and subsequent removing the protecting groups with CF3CO2H. I-contg. pharmaceutical ***compns*** . were reported.

=> d his

(FILE 'HOME' ENTERED AT 13:14:57 ON 13 SEP 2003)

FILE 'MEDLINE, CAPLUS, BIOSIS, EMBASE, SCISEARCH, AGRICOLA' ENTERED AT 13:15:17 ON 13 SEP 2003
L1 411 S HIS-PHE-ARG-TRP

```
L2            73 S HIS-D-PHE-ARG-TRP
L3           462 S L1 OR L2
L4            20 S COMPOSITION (P) L3
L5             9 DUPLICATE REMOVE L4 (11 DUPLICATES REMOVED)

=> s sexual (w) (response or dysfunction)
L6         17401 SEXUAL (W) (RESPONSE OR DYSFUNCTION)

=> s l6 (p) l3
L7             3 L6 (P) L3

=> duplicate remove l7
DUPLICATE PREFERENCE IS 'CAPLUS, BIOSIS'
KEEP DUPLICATES FROM MORE THAN ONE FILE?  Y/(N):n
PROCESSING COMPLETED FOR L7
L8             3 DUPLICATE REMOVE L7 (0 DUPLICATES REMOVED)

=> d l8 1-3 ibib abs

L8   ANSWER 1 OF 3  BIOSIS  COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC. on STN
ACCESSION NUMBER:   2003:323715  BIOSIS
DOCUMENT NUMBER:    PREV200300323715
TITLE:              Compositions and methods for treatment of sexual
                    dysfunction.
AUTHOR(S):          Blood, Christine H.; Shadiack, Annette M. (1); Bernstein,
                    Joanna K.; Herbert, Guy H.
CORPORATE SOURCE:   (1) Sommerset, NJ, USA USA
                    ASSIGNEE: Palatin Technologies, Inc., Cranbury, NJ, USA
PATENT INFORMATION: US 6579968 June 17, 2003
SOURCE:             Official Gazette of the United States Patent and Trademark
                    Office Patents, (June 17 2003) Vol. 1271, No. 3, pp. No
                    Pagination. http://www.uspto.gov/web/menu/patdata.html.
                    e-file.
                    ISSN: 0098-1133.
DOCUMENT TYPE:      Patent
LANGUAGE:           English
AB   Compositions and methods are provided for treatment of   ***sexual***
       ***dysfunction***   in mammals, including male   ***sexual***
       ***dysfunction***   , such as erectile dysfunction, and female
       ***sexual***     ***dysfunction***   . In one embodiment, a peptide-based
     composition including the peptide sequence Ac-Nle-cyclo(-Asp-  ***His***
     -  ***D***  -  ***Phe***  -  ***Arg***  -  ***Trp***  -Lys)-OH is
     administered. Methods of administration include injection, oral, nasal and
     mucosal administration.

L8   ANSWER 2 OF 3  CAPLUS  COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER:        2002:595493  CAPLUS
DOCUMENT NUMBER:         137:145614
TITLE:                   Pharmaceutical compositions containing a peptide for
                         treatment of sexual dysfunction
INVENTOR(S):             Blood, Christine H.; Shadiack, Annette M.; Bernstein,
                         Joanna K.; Herbert, Guy H.
PATENT ASSIGNEE(S):      USA
SOURCE:                  U.S. Pat. Appl. Publ., 20 pp., Cont.-in-part of U.S.
                         Ser. No. 606,501.
                         CODEN: USXXCO
DOCUMENT TYPE:           Patent
LANGUAGE:                English
FAMILY ACC. NUM. COUNT:  2
PATENT INFORMATION:

     PATENT NO.        KIND  DATE          APPLICATION NO.  DATE
     ---------------   ----  --------      ---------------  --------
     US 2002107182      A1   20020808      US 2002-40547    20020104
     US 6579968         B1   20030617      US 2000-606501   20000628
PRIORITY APPLN. INFO.:                  US 1999-142346P  P  19990629
                                        US 2000-194987P  P  20000405
                                        US 2000-606501   A2 20000628
AB   Compns. and methods are provided for treatment of   ***sexual***
       ***dysfunction***   in mammals, including male   ***sexual***
       ***dysfunction***   , such as erectile dysfunction, and female
       ***sexual***     ***dysfunction***   .  In one embodiment, a peptide-based
     compn. including the peptide sequence Ac-Nle-cyclo(-Asp-  ***His***  -
       ***D***  -  ***Phe***  -  ***Arg***  -  ***Trp***  -Lys)-OH (I) is
     administered.  Methods of administration include injection, oral, nasal
     and mucosal administration.  I was dissolved in a 50 mM citrate, pH
     approx. 6.0, at a concn. of .825 mg per mL to obtain a nasal soln.  Nasal
```

administration of I at a concn. of 25 .mu.k/kg induced 100% penile erection in rats for 2 times in 30 min.

L8 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 2001:12284 CAPLUS
DOCUMENT NUMBER: 134:76409
TITLE: Compositions and methods for treatment of sexual dysfunction
INVENTOR(S): Blood, Christine H.; Shadiack, Annette M.; Bernstein, Joanna K.; Herbert, Guy W.
PATENT ASSIGNEE(S): Palatin Technologies Inc., USA
SOURCE: PCT Int. Appl., 33 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| WO 2001000224 | A1 | 20010104 | WO 2000-US18217 | 20000629 |
| W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | |
| RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG | | | | |
| US 6579968 | B1 | 20030617 | US 2000-606501 | 20000628 |
| BR 2000012200 | A | 20020326 | BR 2000-12200 | 20000629 |
| EP 1196184 | A1 | 20020417 | EP 2000-950283 | 20000629 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO | | | | |
| JP 2003503357 | T2 | 20030128 | JP 2001-505933 | 20000629 |

PRIORITY APPLN. INFO.:
US 1999-142346P P 19990629
US 2000-194987P P 20000405
US 2000-606501 A 20000628
WO 2000-US18217 W 20000629

AB Compns. and methods are provided for the treatment of ***sexual*** ***dysfunctions*** in mammals, such as erectile dysfunction and female ***sexual*** ***dysfunction*** . In one embodiment, a peptide-based compn. including the peptide sequence Ac-Nle-cyclo(-Asp- ***His*** - ***D*** - ***Phe*** - ***Arg*** - ***Trp*** -Lys)-OH is administered. Methods of administration include injection, oral, nasal and mucosal administration.

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> s melanocortin receptor specific peptide
5 FILES SEARCHED...
L9 1 MELANOCORTIN RECEPTOR SPECIFIC PEPTIDE

=> s alpha-MSH
L10 13509 ALPHA-MSH

=> s l10 (p) (fragment or analog)
L11 1852 L10 (P) (FRAGMENT OR ANALOG)

=> s (l9 or l11) (p) l6
L12 2 (L9 OR L11) (P) L6

=> duplicate remove l12
PROCESSING COMPLETED FOR L12
L13 2 DUPLICATE REMOVE L12 (0 DUPLICATES REMOVED)

=> d l13 1-2 ibib abs

L13 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 2003:58220 CAPLUS
DOCUMENT NUMBER: 138:117676
TITLE: Linear and cyclic melanocortin receptor-specific peptides, and therapeutic use
INVENTOR(S): Sharma, Shubh D.; Shadiack, Annette M.; Yang, Wei; Rajpurohit, Ramesh

PATENT ASSIGNEE(S): Palatin Technologies, Inc., USA
SOURCE: PCT Int. Appl., 55 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| WO 2003006620 | A2 | 20030123 | WO 2002-US22196 | 20020711 |

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2001-304836P P 20010711
OTHER SOURCE(S): MARPAT 138:117676
AB Linear and cyclic peptides are provided which are specific to melanocortin receptors and which exhibit agonist, antagonist, or mixed agonist-antagonist activity. The peptides of the invention may be used to treat e.g. erectile dysfunction and eating disorders.

L13 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 2003:604743 CAPLUS
TITLE: PT-141: a melanocortin agonist for the treatment of sexual dysfunction
AUTHOR(S): Molinoff, P. B.; Shadiack, A. M.; Earle, D.; Diamond, L. E.; Quon, C. Y.
CORPORATE SOURCE: Palatin Technologies, Inc., Cranbury, NJ, 08512, USA
SOURCE: Annals of the New York Academy of Sciences (2003), 994(Melanocortin System), 96-102
CODEN: ANYAA9; ISSN: 0077-8923
PUBLISHER: New York Academy of Sciences
DOCUMENT TYPE: Journal
LANGUAGE: English
AB PT-141, a synthetic peptide ***analog*** of . ***alpha*** .-***MSH*** , is an agonist at melanocortin receptors including the MC3R and MC4R, which are expressed primarily in the central nervous system. Administration of PT-141 to rats and nonhuman primates results in penile erections. Systemic administration of PT-141 to rats activates neurons in the hypothalamus as shown by an increase in c-Fos immunoreactivity. Neurons in the same region of the central nervous system take up pseudorabies virus injected into the corpus cavernosum of the rat penis. Administration of PT-141 to normal men and to patients with erectile dysfunction resulted in a rapid dose-dependent increase in erectile activity. The results suggest that PT-141 holds promise as a new treatment for ***sexual*** ***dysfunction*** .
REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d his

(FILE 'HOME' ENTERED AT 13:14:57 ON 13 SEP 2003)

FILE 'MEDLINE, CAPLUS, BIOSIS, EMBASE, SCISEARCH, AGRICOLA' ENTERED AT 13:15:17 ON 13 SEP 2003

| | | |
|---|---|---|
| L1 | 411 | S HIS-PHE-ARG-TRP |
| L2 | 73 | S HIS-D-PHE-ARG-TRP |
| L3 | 462 | S L1 OR L2 |
| L4 | 20 | S COMPOSITION (P) L3 |
| L5 | 9 | DUPLICATE REMOVE L4 (11 DUPLICATES REMOVED) |
| L6 | 17401 | S SEXUAL (W) (RESPONSE OR DYSFUNCTION) |
| L7 | 3 | S L6 (P) L3 |
| L8 | 3 | DUPLICATE REMOVE L7 (0 DUPLICATES REMOVED) |
| L9 | 1 | S MELANOCORTIN RECEPTOR SPECIFIC PEPTIDE |
| L10 | 13509 | S ALPHA-MSH |
| L11 | 1852 | S L10 (P) (FRAGMENT OR ANALOG) |
| L12 | 2 | S (L9 OR L11) (P) L6 |
| L13 | 2 | DUPLICATE REMOVE L12 (0 DUPLICATES REMOVED) |

```
=> s blood christine/au
L14             8 BLOOD CHRISTINE/AU

=> s shadiack annette/au
L15             2 SHADIACK ANNETTE/AU

=> s berstein joanna/au
L16             0 BERSTEIN JOANNA/AU

=> s l14 or l15
L17            10 L14 OR L15

=> s l3 and l17
L18             0 L3 AND L17

=> d his

     (FILE 'HOME' ENTERED AT 13:14:57 ON 13 SEP 2003)

     FILE 'MEDLINE, CAPLUS, BIOSIS, EMBASE, SCISEARCH, AGRICOLA' ENTERED AT
     13:15:17 ON 13 SEP 2003
L1            411 S HIS-PHE-ARG-TRP
L2             73 S HIS-D-PHE-ARG-TRP
L3            462 S L1 OR L2
L4             20 S COMPOSITION (P) L3
L5              9 DUPLICATE REMOVE L4 (11 DUPLICATES REMOVED)
L6          17401 S SEXUAL (W) (RESPONSE OR DYSFUNCTION)
L7              3 S L6 (P) L3
L8              3 DUPLICATE REMOVE L7 (0 DUPLICATES REMOVED)
L9              1 S MELANOCORTIN RECEPTOR SPECIFIC PEPTIDE
L10         13509 S ALPHA-MSH
L11          1852 S L10 (P) (FRAGMENT OR ANALOG)
L12             2 S (L9 OR L11) (P) L6
L13             2 DUPLICATE REMOVE L12 (0 DUPLICATES REMOVED)
L14             8 S BLOOD CHRISTINE/AU
L15             2 S SHADIACK ANNETTE/AU
L16             0 S BERSTEIN JOANNA/AU
L17            10 S L14 OR L15
L18             0 S L3 AND L17

=> log y
COST IN U.S. DOLLARS                            SINCE FILE      TOTAL
                                                   ENTRY    SESSION
FULL ESTIMATED COST                                78.35      78.56

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)      SINCE FILE      TOTAL
                                                   ENTRY    SESSION
CA SUBSCRIBER PRICE                                -5.21      -5.21

STN INTERNATIONAL LOGOFF AT 13:24:23 ON 13 SEP 2003
```